Privi Speciality Chemicals Limited has announced that its Board of Directors will convene on February 09, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key milestone in the company's regular financial reporting cycle.

Board Meeting Details

The board meeting has been scheduled in compliance with SEBI regulations, specifically under Regulation 29(1)(a) and 29(1)(e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will take place at the company's board room located at Privi House, A-71, TTC, Thane Belapur Road, Koparkhairne, Navi Mumbai, Maharashtra.

Financial Results Review

The primary agenda involves consideration and approval of unaudited standalone and consolidated financial results under Ind-AS for the quarter and nine months ended December 31, 2025. This quarterly review will provide stakeholders with insights into the company's operational and financial performance during the third quarter of fiscal year 2026.

Trading Window Restrictions

In accordance with insider trading regulations, the company has implemented trading window restrictions for designated persons and their immediate relatives. The trading window, which closed on January 01, 2026, will remain shut until the financial results are announced.

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory requirements and commitment to transparent financial reporting. The intimation has been communicated to both BSE Limited (Script Code: 530117) and National Stock Exchange of India Ltd (Symbol: PRIVISCL), ensuring compliance with listing obligations. Additionally, the information has been made available on the company's official website at www.privi.com for public access and transparency.

SBI Mutual Fund has significantly increased its stake in privi speciality chemicals through a substantial market acquisition, crossing the regulatory threshold that requires mandatory disclosure under SEBI regulations. The acquisition demonstrates institutional confidence in the specialty chemicals manufacturer.

Acquisition Details

On December 31, 2025, SBI Mutual Fund under its various schemes acquired 22.40 lakh shares of Privi Speciality Chemicals Limited through market purchases. This acquisition increased the fund's total shareholding from 14.23 lakh shares to 36.63 lakh shares, representing a significant jump in ownership percentage.

Regulatory Compliance

The acquisition triggered reporting requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, as the fund's holding crossed the 5% threshold. SBI Funds Management Limited, through Chief Compliance Officer & Company Secretary Vinaya Datar, filed the mandatory disclosure on January 01, 2026.

The disclosure was submitted to Privi Speciality Chemicals' Company Secretary & Compliance Officer Ms. Ashwini Saumil Shah, along with copies to both the National Stock Exchange of India Limited and BSE Limited, where the company's shares are listed.

Company Share Capital Structure

Privi Speciality Chemicals maintains a stable share capital structure with no changes resulting from this transaction. The company's equity share capital remains at ₹39.06 crores, consisting of 3.91 crore equity shares with a face value of ₹10.00 each.

Transaction Characteristics

The acquisition was executed entirely through market purchases of equity shares, with no involvement of warrants, convertible securities, or other instruments. SBI Mutual Fund confirmed that it does not belong to the promoter or promoter group of Privi Speciality Chemicals, maintaining its status as an institutional investor.

The substantial acquisition reflects institutional interest in the specialty chemicals sector, with SBI Mutual Fund now holding a significant minority stake in the company. The fund's increased position establishes it as a notable shareholder in Privi Speciality Chemicals' ownership structure.